Clinical Trials Page

 
  L-MARC Home Page  ::  
   

Cholesterol & Lipid Clinical Trials

 

A PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, DRUG INTERACTION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECT ON ATORVASTATIN PHARMACOKINETICS OF ETC-1002 ADDED TO ATORVASTATIN 10 MG/DAY IN SUBJECTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2013)

A MULTICENTER, RANDOMIZED, ACTIVE COMPARATOR, PLACEBO-CONTROLLED, DOUBLE-BLIND PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF LCQ908 ALONE AND IN COMBINATION WITH FENOFIBRATE OR LOVAZA IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 2013)

A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ACCESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE IV DOSES OF PF-05231023 IN OBESE HYPERLIPIDEMIC ADULT SUBJECTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS ON A BACKGROUND OF ATORVASTATIN
(PRINCIPAL INVESTIGATOR, 2013)

A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF REGN727 ADDED-ON TO ATORVASTATIN VERSUS EZETIMIBE ADDED-ON TO ATORVASTATIN VERSUS ATORVASTATIN DOSE INCREASE VERSUS SWITCH TO ROSUVASTATIN IN PATIENTS WHO ARE NOT CONTROLLED ON ATORVASTATIN
(PRINCIPAL INVESTIGATOR, 2013)

A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF REGN727 ADDED-ON TO ROSUVASTATIN VERSUS EZETIMIBE ADDED-ON TO ROSUVASTATIN VERSUS ROSUVASTATIN DOSE INCREASE IN PATIENTS WHO ARE NOT CONTROLLED ON ROSUVASTATIN
(PRINCIPAL INVESTIGATOR, 2013)

A PHASE 2 EFFICACY AND SAFETY DOSE-RANGING STUDY OF LY3015014 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2013)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO AND EZETIMIBE-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF LIPID LOWERING MONOTHERAPY WITH AMG 145 IN SUBJECTS WITH A 10-YEAR FRAMINGHAM RISK SCORE OF 10% OR LESS
(PRINCIPAL INVESTIGATOR, 2013)

A MULTICENTER, CONTROLLED, OPEN-LABEL EXTENSTION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 145
(PRINCIPAL INVESTIGATOR, 2013)

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 24-WEEK PILOT STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF LCQ908 IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
(PRINCIPAL INVESTIGATOR, 2013)

CAT-2003-201 (2013): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACODYNAMICS OF CAT-2003 ALONE AND IN COMBINATION WITH A STATIN IN PATIENTS WITH HYPERLIPIDEMIA (PATHWAYS 1)
(PRINCIPAL INVESTIGATOR, 2013)

PRC-4016 (2013): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 12-WEEK PHASE II PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRC-4016 600MG ONCE DAILY VERSUS PLACEBO IN STATIN-NAÏVE OR STATIN-STABLE HYPERTRIGLYCERIDEMIC SUBJECTS
(PRINCIPAL INVESTIGATOR, 2013)

A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 FOLLOWING MONTHLY AND TWICE MONTHLY SUBCUTANEOUS DOSING FOR SIX MONTHS IN HYPERCHOLESTEROLEMIC SUBJECTS ON A STATIN
(PRINCIPAL INVESTIGATOR, 2012)

HPS 3 / TIMI 55: REVEAL (RANDOMIZED EVALUATION OF THE EFFECTS OF ANACETRAPIB THROUGH LIPID MODIFICATION): A LARGE SCALE, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE CLINICAL EFFECTS OF ANACETRAPIB AMONG PEOPLE WITH ESTABLISHED VASCULAR DISEASE
(PRINCIPAL INVESTIGATOR, 2012)

A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACYAND SAFETY OF ADD-ON EPANOVA TO STATIN THERAPY IN SUBJECTS WITH PERSISTENT HYPERTRIGLYCERIDEMIA AND HIGH RISK FOR CARDIOVASCULAR DISEASE
(PRINCIPAL INVESTIGATOR, 2012)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO AND EZETIMIBE CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF AMG 145 IN SUBJECTS WITH A 10 YEAR FRAMINGHAM RISK SCORE OF 10% OR LESS AND CURRENTLY NOT RECEIVING PRESCRIPTION LIPID-LOWERING THERAPY.
(PRINCIPAL INVESTIGATOR, 2012)

A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF AMR101 ON CARDIOVASCULAR HEALTH AND MORTALITY IN HYPERTRIGLYCERIDEMIC PATIENTS WITH CARDIOVASCULAR DISEASE OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE: REDUCE-IT (REDUCTION IN CARDIOVASCULAR EVENTS WITH EPA - INTERVENTION TRIAL)
(PRINCIPAL INVESTIGATOR, 2012)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE LONG-TERM TOLERABILITY AND DURABLE EFFICACY OF AMG 145 ON LDL-C IN HYPERLIPIDEMIC SUBJECTS. DESCARTES: DURABLE EFFECT OF PCSK9 ANTIBODY COMPARED WITH PLACEBO STUDY
(PRINCIPAL INVESTIGATOR, 2012)

EFFICACY, SAFETY, AND MECHANISM OF ACTION OF A SUPPLEMENT CAPSULE CONTAINING L. REUTERI CARDIOVIVA NCIMB 30242 ON MANAGING CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC ADULTS
(PRINCIPAL INVESTIGATOR, 2012)

A RANDOMIZED, PLACEBO AND EZETIMIBE CONTROLLED, DOSE-RANGING STUDY TO EVALUATE TOLERABILITY AND EFFICACY OF AMG 145 ON LDL-C IN HYPERCHOLESTEROLEMIC SUBJECTS WITH A 10 YEAR FRAMINGHAM RISK SCORE OF 10% ORLESS
(PRINCIPAL INVESTIGATOR, 2012)

A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
(PRINCIPAL INVESTIGATOR, 2012)

A 2-YEAR EXTENSION TO: A 76-WEEK, WORLDWIDE, MULTIC ENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH CORONARY HEART DISEASE (CHD) OR CHD RISK-EQUIVALENT DISEASE: REVERSAL PERIOD EXTENDED FROM 12 WEEKS TO 1 YEAR
(PRINCIPAL INVESTIGATOR, 2012)

EFFICACY AND SAFETY OF EPANOVA® IN SEVERE HYPERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 2011)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY OF LIPID-LOWERING EFFECTS OF XUEZHIKANG (XZK) IN PATIENTS WITH HYPERLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2011)

A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLERMIA AND HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED WITH
ATORVASTATIN 10 MG: A COMPARISON OF THE EFFICACY AND SAFETY OF SWITCHING TO COADMINISTRATION EZETIMIBE AND ATORVASTATIN VERSUS DOUBLING THE DOSE OF ATORVASTATIN OR SWITCHING TO ROSUVASTATIN
(PRINCIPAL INVESTIGATOR, 2011)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO ASSESS EFFICACY AND SAFETY OF AKR-963 THERAPY IN SUBJECTS WITH SEVERE HYERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 2011)

A PLACEBO-CONTROLLED RANDOMIZED, DOUBLE-BLIND PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETC-1002 IN SUBJECTS WITH AND EITHER NORMAL OR ELEVATED TRIGLYCERIDES
(PRINCIPAL INVESTIGATOR, 2011)

A PHASE III, MULTICENTER, DOUBLE-BLIND, CROSSOVER DESIGN STUDY TO EVALUATE LIPID-ALTERING EFFICACY AND SAFETY OF 1 G / 10 MG EXTENDED-RELEASE NIACIN/LAROPIPRANT/SIMVASTATIN COMBINATION TABLETS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2011)

A PHASE III MULTICENTER, DOUBLE-BLIND, CROSSOVER DESIGN STUDY TO EVALUATE LIPID-ALTERING EFFICACY AND SAFETY OF EXTENDED-RELEASE NIACIN/LAROPIPRANT/SIMVASTATIN COMBINATION TABLET IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2011)

A 2-YEAR EXTENSION TO: A 76-WEEK, WORLDWIDE, MULTIC ENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH CORONARY HEART DISEASE (CHD) OR CHD RISK-EQUIVALENT DISEASE
(PRINCIPAL INVESTIGATOR, 2010)

A STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ADMINISTERING MULTIPLE ORAL DOSES OF GSK1292263 ALONE AND WITH ATORVASTATIN
(PRINCIPAL INVESTIGATOR, 2010)

A MULTI - CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED D STUDY ASSESSING THE EFFICACY, SAFETY AND TOLERABILITY OF DIAZOXIDE CHOLINE CONTROLLED-RELEASE TABLETS (DCCR) IN SUBJECTS WITHOUT DIABETES MELLITUS HAVING VERY HIGH FASTING TRIGLYCERIDE LEVELS, WITH DOUBLE-BLIND DCCR-FENOFIBRATE COMBINATION EXTENSION
(PRINCIPAL INVESTIGATOR, 2010)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF THE EFFECTS OF CHITIN-GLUCAN ON OXIDIZED LDL
(PRINCIPAL INVESTIGATOR, 2010)

A PHASE 3, MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, 12-WEEK STUDY TO EVALUATE THE EFFECT OF TWO DOSES OF AMR101 ON FASTING SERUM TRIGLYCERIDE LEVELS IN PATIENTS WITH PERSISTENT HIGH TRIGLYCERIDE LEVELS > 200 MG/DL AND<500 MG/DL) DESPITE STATIN THERAPY: THE AMR101 ANCHOR STUDY
(PRINCIPAL INVESTIGATOR, 2010)

A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE/ATORVASTATIN 10 MG/20MG FIXED-DOSE COMBINATION TABLET COMPARED TO CO-ADMINISTRATION OF MARKETED EZETIMIBE 10MG AND ATORVASTATIN 20MG IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2010)

A RANDOMIZED, SINGLE-BLIND, SINGLE RESEARCH SITE, COMPARISON OF COLESEVELAM HCL POWDER VERSUS GENERIC QUESTRAN (CHOLESTYRAMINE) THROUGH USE OF THE BILE ACID SEQUESTRANT ACCEPTABILITY (BASA) SCALE IN GENERALLY HEALTHY SUBJECTS
(PRINCIPAL INVESTIGATOR, 2010)

A RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED, SINGLE RESEARCH SITE, BILE ACID SEQUESTRANT ACCEPTABILITY (BASA) SCALE PILOT VALIDATION STUDY IN GENERALLY HEALTHY SUBJECTS
(PRINCIPAL INVESTIGATOR, 2010)

A WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM, EFFICACY, SAFETY, AND TOLERABILITY OF EXTENDED-RELEASE (ER) NIACIN AND LAROPIPRANT (ERN/LRPT) IN PATIENTS WITH DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2010)

A CLINICAL OUTCOMES STUDY OF DARAPLADIB VERSUS PLACEBO IN SUBJECTS WITH CHRONIC CORONARY HEART DISEASE TO COMPARE THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE). THE STABILIZATION OF ATHEROSCLEROTIC PLAQUE BY INITIATION OF DARAPLADIB THERAPY TRIAL (STABILITY)
(PRINCIPAL INVESTIGATOR 2009)

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, DOSE-RESPONSE EFFICACY AND SAFETY STUDY OF SCH 900271 COMPARED TO PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA (FAMILIAL AND NONFAMILIAL) OR MIXED HYPER LIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2009)

A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND, 12-WEEK STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF AMR101 IN PATIENTS WITH FASTING TRIGLYCERIDE LEVELS 500 MG/DL AND < 2000MG/DL: THE AMR101 MARINE STUDY
(PRINCIPAL INVESTIGATOR, 2009)

A TWO PART, MULTICENTER PHASE IIA, PLACEBO CONTROLLED STUDY, TO EXAMINE THE SAFETY, TOLERABILITY, AND EFFECTS OF GSK256073 ON LIPIDS IN SUBJECTS WITH DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2009)

A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF PATIENTS WITH CARDIOVASCULAR DISEASE AND DIABETES MELLITUS NOT ADEQUATELY CONTROLLED WITH SIMVASTATIN 20 MG OR ATORVASTATIN 10MG: A COMPARISON OF SWITCHING TO A COMBINATION TABLE EZETIMIBE/SIMVASTATIN (10MG/20MG) VERSUS SWITCHING TO ROSUVASTATIN 10MG OR DOUBLING THE STATIN DOSE
(PRINCIPAL INVESTIGATOR, 2009)

A 12-WEEK, RANDOMIZED, SEMI DOUBLE-BLINDED STUDY EVALUATING THE EFFECTS OF DAILY ORAL HIGH-DOSE ATORVASTATIN OR BMS-582949 ON ATHEROSCLEROTIC PLAQUE INFLAMMATION AS DETERMINED BY FDG-PET IN HIGH RISK ATHEROSCLEROTIC PATIENTS.
( PRINCIPAL INVESTIGATOR, 2009)

AN 8-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, FOUR-ARM, PARALLEL-GROUP COMPARING THE SAFETY AND EFFICACY OF ABT-143 TO SIMVASTATIN IN SUBJECTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2009)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LIPID-MODIFYING EFFECT AND TOLERABILITY OF MK-1903 IN PATIENTS WITH DYSLIPIDEMIA
PRINCIPAL INVESTIGATOR (2009)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DIFFERENT DOSES OF SLX-4090 IN COMBINATION WITH STATIN VS STATIN MONO-THERAPY IN PATIENTS WITH HYPERLIPIDEMIA
PRINCIPAL INVESTIGATOR (2009)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, TITRATION STUDY TO EVAULATE THE EFFICACY AND SAFETY OF EZETIMIBE ADDED ON TO ROSUVASTATIN VERSUS UP TITRATION OF ROSUVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AT RISK FOR CORONARY HEART DISEASE.
PRINCIPAL INVESTIGATOR (2009)

A DOUBLE-BLIND, RANDOMIZED, 12-MONTH, PARALLEL GROUP, FIXED DOSE, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AVE5530 25 MG/DAY AND 50 MG/DAY IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 12 MONTH, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LIPID-LOWERING EFFECT, SAFETY AND TOLERABILITY OF AVE5530 25 MG/DAY AND 50 MG/DAY WHEN ADDED TO ONGOING STATIN THERAPY (HMG-COA REDUCTASE INHIBITORS) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AVE5530 WHEN ADDED TO ONGOING STABLE STATIN THERAPY AT HIGH DOSES IN PATIENTS WITH SEVERE PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2008)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF ISIS 301012 (MIPOMERSEN) AS ADD-ON THERAPY IN HIGH RISK HYPERCHOLESTEROLEMIC PATIENTS
PRINCIPAL INVESTIGATOR (2008)

A 76-WEEK, WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF ANACETRAPIB WHEN ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA
PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND TOLERABILITY OF MK-6213 CO-ADMINISTERED WITH ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2008)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DIAZOXIDE CHOLINE IN NON-DIABETIC HYPERTRIGLYCERIDEMIC SUBJECTS
PRINCIPAL INVESTIGATOR (2008)

A DOUBLE-BLIND, RANDOMIZED STUDY TO EVAULATE THE EFFICACY AND SAFETY OF LAPAQUISTAT ACETATE 50 MG OR PLACEBO WHEN COADMINISTERED WITH STATINS IN SUBJECTS WITH HYPERCHOLESTEROLEMIA, WITH AN OPTIONAL OPEN-LABEL EXTENSION
(PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY COMPARING THE SAFETY AND EFFICACY OF ABT-335 IN COMBINATION WITH ATORVASTATIN AND EZETIMIBE TO ATORVASTATIN IN COMBINATION WITH EZETIMIBE IN SUBJECTS WITH COMBINED (ATHEROGENIC) DYSLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE- CONTROLLED DOSE- RANGING STUDY WITH ACTIVE- CONTROLLED LONG TERM SAFETY PHASE TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF MK-6213 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2007) 

AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-475 IN SUBJECTS WITH HYPERCHOLESTEROLEMIA.
PRINCIPAL INVESTIGATOR (2007) 

A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF MBX-8025 IN MODERATELY OBESE HYPERLIPIDEMIC PATIENTS WITH OR WITHOUT CONCOMITANT ATORVASTATIN.
PRINCIPAL INVESTIGATOR (2007) 

AN OBSERVATIONAL SAFETY FOLLOW-UP TRIAL OF THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY IN SUBJECTS WHO PARTICIPATED IN SELECTED TORCETRAPIB/ATORVASTATIN CLINICAL TRIALS
PRINCIPAL INVESTIGATOR (2007) 

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 36-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXTENDED RELEASE (ER) NIACIN/LAROPIPRANT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
PRINCIPAL INVESTIGATOR (2007)

ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDE AND IMPACT ON GLOBAL HEALTH OUTCOMES 2007
PRINCIPAL INVESTIGATOR (2007) 

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE LOW DOSES OF THE MTP-INHIBITOR AEGR-733 ON HEPATIC FAT ACCUMULATION AS MEASURED BY MAGNETIC RESONANCE SPECTROSCOPY
PRINCIPAL INVESTIGATOR (2007) 

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM, 12-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE 10MG WHEN ADDED TO ATORVASTATIN 10MG VERSUS TITRATION TO ATORVASTATIN 20MG AND TO 40MG IN ELDERLY PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH RISK FOR CHD
PRINCIPAL INVESTIGATOR (2007)

A MULTI-CENTER, PROSPECTIVE, LONGITUDINAL, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAILY ADMINISTRATION OF PRAVASTATIN 40 MG OR FENOFIBRATE 160 MG OR PRAVAFEN (COMBINATION OF PRAVASTATIN AND FENOFIBRATE 40/160 MG) FOR 12 WEEKS FOLLOWED BY A 52-WEEK OPEN-LABEL SAFETY PHASE OF THE PRAVAFEN ALONE IN THE TREATMENT OF COMBINED HYPERLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2007)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, “CROSSOVER” DESIGN STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND SAFETY OF MK-0524B COMBINATION TABLET COMPARED TO MK-0524A + SIMVASTATIN COADMINISTRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
PRINCIPAL INVESTIGATOR (2007)

A PHASE 2, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGE-FINDING STUDY OF THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED MD-0727 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2007)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE COMBINATION OF AEGR-733 (FORMERLY BMS 201038) AND ATORVASTATIN 20 MG VS. MONOTHERAPY IN SUBJECTS WITH MODERATE HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2007)

A DOUBLE-BLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LAPAQUISTAT ACETATE 100MG IN THE MORNING VS LAPAQUISTAT ACETATE 100MG IN THE EVENING VS LAPAQUISTAT ACETATE 50MG TWICE DAILY VS PLACEBO IN SUBJECTS WITH HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2007)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FORCED TITRATION STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMACOR, CO-ADMINISTERED WITH OPEN-LABEL ATORVASTATIN THERAPY, IN HYPERTRIGLYCERIDEMIC SUBJECTS
PRINCIPAL INVESTIGATOR (2007)

A YEAR 2, LONG-TERM, OPEN-LABEL, SAFETY EXTENSION STUDY OF THE COMBINATION OF ABT-335 AND STATIN THERAPY FOR SUBJECTS WITH MIXED DYSLIPIDEMIA)
PRINCIPAL INVESTIGATOR (2007)

A PHASE II, PLACEBO-CONTROLLED, DOUBLE-BLIND EXTENSION STUDY OF STUDY NC19453 ASSESSING LONG TERM SAFETY AND EFFICACY OF RO4607381.
PRINCIPAL INVESTIGATOR (2007)

A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE COMBINATION OF ABT-335 AND ROSUVASTATIN COMPARED TO ABT-335 AND ROSUVASTATIN MONOTHERAPY IN SUBJECTS WITH TYPE IIA AND IIB DYSLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2007)

A PHASE II, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, EVALUATING THE EFFICACY AND SAFETY OF RO4607381 OVER A 24-WEEK PERIOD IN PATIENTS WITH CHD OR A CHD RISK EQUIVALENT.
PRINCIPAL INVESTIGATOR (2007)

A WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL STUDY TO EVALUATE THE EFFICACY OF MK-0524 TO IMPROVE TOLERABILITY OF EXTENDED RELEASE NIACIN
PRINCIPAL INVESTIGATOR (2006)

LIPID TREATMENT ASSESSMENT PROJECT 2 (L-TAP2)
PRINCIPAL INVESTIGATOR (2006)

A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0633 IN MEN WITH ATHEROSCLEROTIC DISEASE
PRINCIPAL INVESTIGATOR (2006)

MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN AND NIACIN (EXTENDED RELEASE TABLET) CO-ADMINISTERED IN PATIENTS WITH TYPE IIA OR TYPE IIB HYPERLIPIDEMIA
PRINCIPAL INVESTIGATOR (2006)

A RANDOMIZED, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND REPEAT ORAL DOSES OF GSK256073A IN SUBJECT WITH BORDERLINE HIGH TO HIGH LDL CHOLESTEROL LEVELS
PRINCIPAL INVESTIGATOR (2006)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, TITRATION STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF EZETIMIBE ADDED ON TO ATORVASTATIN 40MG VERSUS UP TITRATION TO ATORVASTATIN 80MG IN HYPERCHOLESTEROLEMIC PATIENTS AT HIGH RISK FOR CORONARY HEART DISEASE NOT ADEQUATELY CONTROLLED ON ATORVASTATIN 40MG.
PRINCIPAL INVESTIGATOR (2006)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, TITRATION STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF EZETIMIBE ADDED ON TO ATORVASTATIN 20MG VERSUS UP TITRATION TO ATORVASTATIN 40MG IN HYPERCHOLESTEROLEMIC PATIENTS AT MODERATELY HIGH RISK FOR CORONARY HEART DISEASE NOT ADEQUATELY CONTROLLED ON ATORVASTATIN 20MG.
PRINCIPAL INVESTIGATOR (2006)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY COMPARING THE SAFETY AND EFFICACY OF FENOFIBRIC ACID AND ATORVASTIN CALCIUM THERAPY TO FENOFIBRIC ACID AND ATORVASTATIN CALCIUM MONOTHERAPY IN SUBJECTS WITH MIXED DYSLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2006)

A WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0524A WHEN GIVEN AS MONOTHERAPY OR ADDED TO ONGOING THERAPY WITH A STATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA. 
PRINCIPAL INVESTIGATOR (2006)

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF: ATORVASTATIN 80MG AND ATORVASTATIN 40MG IN COMBINATION WITH EZETIMIBE 10MG IN PATIENTS NOT ADEQUATELY CONTROLLED ON 40MG OF ATORVASTATIN THERAPY.
PRINCIPAL INVESTIGATOR (2006)

MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXETIMIBE/SIMVASTATIN AND NIACIN (EXTENDED RELEASE TABLET) CO-ADMINISTERED IN PATIENTS WITH TYPE IIA ON TYPE IIB HYPERLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2006)

A LONG-TERM, OPEN-LABEL, SAFETY EXTENSION STUDY OF THE COMBINATION OF FENOFIBRIC ACID AND STATIN THERAPY FOR SUBJECTS WITH MIXED DYSLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2006)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 12 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0524B VERSUS ATORVASTATIN IN PATIENTS WITH MIXED HYPERLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2006)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-DESIGN STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND TOLERABILITY OF MK-0354 IN PATIENTS WITH DYSLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2006)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO ASSES THE EFFICACY, SAFETY, AND TOLERABILITY OF MK-0859 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA
PRINCIPAL INVESTIGATOR (2006)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, "FACTORIAL" DESIGN STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND SAFETY OF MK-0524B (DOSED AS CO ADMINISTERED MK0524A AND SIMVASTATIN TABLETS) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDEMIA.
PRINCIPAL INVESTIGATOR (2006)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED FACTORIAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 AND SIMVASTATIN ALONE AND IN COMBINATION IN SUBJECTS WITH HYPERCHOLESTEROLEMIA.
PRINCIPAL INVESTIGATOR (2006)

A SECOND OPEN-LABEL EXTENSION OF A DOUBLE-BLIND, PARALLEL, PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUNCTIVE OMACOR THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS TREATED WITH ANTARA.
PRINCIPAL INVESTIGATOR (2006)

AN OPEN-LABEL EXTENSION OF A DOUBLE-BLIND, PARALLEL, PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUNCTIVE OMACOR THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS TREATED WITH ANTARA.
PRINCIPAL INVESTIGATOR (2006)

AN OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF COMBINED OMACOR AND SIMVASTATIN THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS.
PRINCIPAL INVESTIGATOR (2006)

PHASE A: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-DESIGN EXTENSION OF THE PHASE IIA CLINICAL EFFICACY STUDY (026-01) TO EVALUATE THE LIPID ALTERING EFFICACY OF MK0524A FORMULATION C COMPARED TO NIASPAN
PRINCIPAL INVESTIGATOR (2005)

PHASE B/C: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 1-YEAR EXTENSION OF THE PHASE IIA CLINICAL EFFICACY STUDY (026-01) TO ASSESS THE TOLERABILITY OF THE MK 0524/NIACIN COMBINATION TABLET
PRINCIPAL INVESTIGATOR (2005)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUNCTIVE OMACOR THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS TREATED WITH ANTARA
PRINCIPAL INVESTIGATOR (2005)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF COMBINED OMACOR AND SIMVASTATIN THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS
PRINCIPAL INVESTIGATOR (2005)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN COMBINATION WITH ZETIA COMPARED TO ZETIA ALONE IN PATIENT WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2005)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 6-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COMBINATION TABLET VERSUS ATORVASTATIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2005)

A PHASE II, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED PARALLEL GROUP STUDY, EVALUATING THE EFFICACY AND SAFETY OF THREE DOSES OF RO4607381 COMBINED WITH PRAVASTATIN OVER A 12 WEEK PERIOD IN PATIENTS WITH LOW OR AVERAGE HDL-C LEVELS
PRINCIPAL INVESTIGATOR (2005)

A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN AND FENOFIBRATE COADMINISTRATION IN PATIENTS WITH MIXED HYPERLIPIDEMIA
PRINCIPAL INVESTIGATOR (2005)

A DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 50MG, 100MG OR PLACEBO WHEN CO-ADMINISTERED WITH ROSUVASTATIN (10 OR 20MG) IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA.
PRINCIPAL INVESTIGATOR (2005)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 (50MG OR 100 MG) WHEN CO-ADMINISTERED WITH ATORVASTATIN (10MG TO 40MG) IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2005)

AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-475 100 MG IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA
PRINCIPAL INVESTIGATOR (2005)

A DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 100 MG VERSUS PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2005)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 1-YEAR EXTENSION OF THE PHASE IIA CLINICAL EFFICACY STUDY (026-01) TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET
PRINCIPAL INVESTIGATOR (2005)

A PHASE II, RANDOMIZED, DOSE-RANGING, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERABILITY STUDY OF ETC-642 IN PATIENTS WITH STABLE ATHEROSCLEROSIS
PRINCIPAL INVESTIGATOR (2005)

A MULTI-CENTER, 52 WEEK, OPEN-LABEL EXTENSION STUDY (FROM STUDIES WEL-301, WEL-302, AND WEL-303) TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF WELCHOL IN TYPE 2 DIABETIC PATIENTS
PRINCIPAL INVESTIGATOR (2005)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE, PARALLEL STUDY TO COMPARE THE SAFETY AND EFFICACY OF FENOFIBRATE OR EZETIMIBE AS ADD-ON THERAPY TO ATORVASTATIN IN SUBJECTS WITH COMBINED HYPERLIPIDEMIA, TYPICAL OF THE METABOLIC SYNDROME.
PRINCIPAL INVESTIGATOR (2005)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ENDPOINT SELECTION AND QUESTIONNAIRE VALIDATION STUDY TO ASSESS THE NIACIN INDUCED FLUSHING CAUSED BY NIACIN
PRINCIPAL INVESTIGATOR (2004)

PART A: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF MK-0524 COMPARED TO PLACEBO
PRINCIPAL INVESTIGATOR (2004)

PART B: A DOSE-RANGING STUDY TO EVALUATE THE TOLERABILITY OF MK-0524 AND ITS EFFECTS ON NIACIN-INDUCED FLUSHING IN LIPID CLINIC PATIENTS AND/OR NORMAL HEALTHY SUBJECTS
PRINCIPAL INVESTIGATOR (2004)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 1-YEAR EXTENSION OF THE PHASE II A DOSE SELECTION STUDY TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET
PRINCIPAL INVESTIGATOR (2004)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 1-YEAR EXTENSION OF THE PHASE II B DOSE SELECTION STUDY TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET
PRINCIPAL INVESTIGATOR (2004)

A DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-475 (100 MG) VS. PLACEBO WHEN COADMINISTERED WITH ATORVASTATIN (10 OR 20 MG) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2004)

A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, 1-YEAR EXTENSION OF THE PHASE IIA ENDPOINT VALIDATION STUDY (015-01) TO ASSESS THE TOLERABILITY OF THE MK-0524/NIACIN COMBINATION TABLET.
PRINCIPAL INVESTIGATOR (2004)

A DOUBLE-BLIND, RANDOMISED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF TAK-475 ALONE OR CO-ADMINISTERED WITH ATORVASTATIN IN PATIENTS WITH PRIMARY DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR (2004)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND SAFETY OF THE EZETIMIBE/SIMVASTATIN COMBINATION TABLET VERSUS ROSUVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA.
PRINCIPAL INVESTIGATOR (2004)

A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY AND SAFETY OF 130MG OF RELIANT FENOFIBRATE, WITH AND WITHOUT FOOD, VERSUS A MATCHING PLACEBO, COMBINED WITH A LOW SATURATED-FAT DIET IN SUBJECTS WITH HYPERTRIGLYCERIDEMIA AND METABOLIC SYNDROME.
PRINCIPAL INVESTIGATOR (2004)

THE COMPELL STUDY: AN OPEN-LABEL, COMPARATIVE EFFICACY EVALUATION OF LIPID LEVELS WHEN TREATED WITH NIASPAN AND STATIN OR OTHER LIPID-MODIFYING THERAPIES
PRINCIPAL INVESTIGATOR (2004)

PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP EVALUATION OF THE FIXED COMBINATION TORCETRAPIB/ATORVASTATIN, ADMINSTERED ORALLY, ONCE DAILY (QD), COMPARED WITH ATORVASTATIN ALONE, ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN SUBJECTS WITH CORONARY HEART DISEASE OR RISK EQUIVALENTS
PRINCIPAL INVESTIGATOR (2004)

A 26 - WEEK, DOUBLE BLIND, RANDOMIZED, MULTI-CENTRE, PHASE IIIB, PARALLEL GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF ROSUVASTATIN (40 MG) WITH ATORVASTATIN (80MG) IN SUBJECTS WITH HYPERCHOLESTEROLEMIA AND CORONARY HEART DISEASE OR CHD RISK EQUIVALENTS. POLARIS - PROSPECTIVE OPTIMISATION OF LIPIDS BY ATORVASTATIN OR ROSUVASTATIN INVESTIGATED IN HIGH-RISK SUBJECTS WITH HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2004)

A 6 - WEEK OPEN-LABEL, RANDOMISED, MULTICENTRE, PHASE IIIB, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF ROSUVASTATIN (10MG) WITH ATORVASTATIN (20MG) IN SUBJECTS WITH HYPERCHOLESTEROLAEMIA AND EITHER A HISTORY OF CORONARY HEART DISEASE (CHD) OR CLINICAL EVIDENCE OF ATHEROSCLEROSIS OR A CHD RISK EQUIVALENT (10 YEAR RISK SCORE OF > 20%). PULSAR - A PROSPECTIVE STUDY TO EVALUATE THE UTILITY OF LOW DOSES OF THE STATINS ATORVASTATIN AND ROSUVASTATIN
PRINCIPAL INVESTIGATOR (2004)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN TYPE 2 DIABETICS WITH INADEQUATE GLYCEMIC CONTROL ON INSULIN THERAPY ALONE OR INSULIN THERAPY IN COMBINATION WITH OTHER ORAL ANTI-DIABETIC AGENTS
PRINCIPAL INVESTIGATOR (2004)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN TYPE 2 DIABETICS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN THERAPY OR METFORMIN THERAPY IN COMBINATION WITH OTHER ORAL ANTI-DIABETIC AGENTS
PRINCIPAL INVESTIGATOR (2004)

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP, MULTICENTER STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF FIXED COMBINATION TORCETRAPIB/ATORVASTATIN ADMINISTERED ORALLY, ONCE DAILY FOR 6 MONTHS, COMPARED WITH ATORVASTATIN ALONE OR PLACEBO, IN SUBJECTS WITH MIXED DYSLIPIDEMIA
PRINCIPAL INVESTIGATOR (2004)

A MULTI-CENTER, THREE STAGED, RANDOMIZED, PARALLEL GROUP, SEQUENTIAL, DOUBLE-BLIND, FENOFIBRATE-AND PLACEBO-CONTROLLED DOSE-RESPONSE EVALUATION OF THE SAFETY, TOLERABILITY, AND EFFECTS ON PLASMA HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND TRIGLYCERIDES (TG) OF EIGHT WEEKS TREATMENT WITH ??? IN OTHERWISE HEALTHY SUBJECTS WITH LOW HDL-C, MILDLY TO MODERATELY ELEVATED TRIGLYCERIDES, AND NORMAL LOW-DENSITY LIPOPROTEIN CHOLESTEROL
PRINCIPAL INVESTIGATOR (2003)

A MULITCENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 6 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE 10-MG / DAY WHEN ADDED TO ONGOING THERAPY WITH A STATIN VERSUS STATIN THERAPY ALONE, IN PATIENTS WITH HYPERCHOLESTEROLEMIA WHO HAVE NOT REACHED NCEP ATP III TARGET LDL-C LEVEL
(PRINCIPAL INVESTIGATOR 2003)

EVALUATION OF THE EFFICACY AND SAFETY OF FENOFIBRATE AND EZETIMIBE CO-ADMINISTRATION IN PATIENTS WITH MIXED HYPERLIPIDEMIA
(PRINCIPAL INVESTIGATOR 2003)

EFFICACY OF WELCHOL AS AN ADD-ON TO SIMVASTATIN
(PRINCIPAL INVESTIGATOR 2003)

EFFICACY OF WELCHOL AS AN ADD-ON TO PRAVASTATIN
(PRINCIPAL INVESTIGATOR 2003)

EFFICACY OF WELCHOL AS AN ADD-ON TO ATORVASTATIN
(PRINCIPAL INVESTIGATOR 2003)

PHASE 2, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PARALLEL GROUP, DOSE RANGING STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMOKINETICS OF C P - 529, 414 AND OPEN LABEL ATORVASTATIN WHEN CONCURRENTLY ADMINISTERED ORALLY ONCE DAILY (QD) FOR 12 WEEKS TO SUBJECTS WITH ELEVATED LOW DENSITY LIPOPROTEIN CHOLESTEROL, AND WITHOUT OVERT CARDIOVASCULAR DISEASE
(PRINCIPAL INVESTIGATOR 2002)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, "FACTORIAL" DESIGN STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND SAFETY OF EZETIMIBE / SIMVASTATIN COMBINATION TABLET IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 2002)

MULTIPLE-DOSE, COMPARATIVE STUDY OF PITAVASTATIN (NK 104) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2002)

A MULTICENTER, EIGHT-WEEK, TREATMENT, SINGLE STEP TITRATION, OPEN-LABEL STUDY ASSESSING THE PERCENTAGE OF DYSLIPIDEMIC PATIENTS ACHIEVING LDL CHOLESTEROL TARGET WITH ATORVASTATIN STARTING DOSES OF 10 MG;, 20 MG, 40 MG, AND 80MG
(PRINCIPAL INVESTIGATOR, 2002)

A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF CP - 529,414 ADMINISTERED ORALLY FOR 8 WEEKS TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2002)

A 6-WEEK, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROSUVASTATIN AND ATORVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN AFRICAN AMERICAN SUBJECTS
(PRINCIPAL INVESTIGATOR, 2002)

AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PHASE IIIB, PARALLEL GROUP SWITCHING STUDY TO COMPARE THE EFFICACY AND SAFETY OF LIPID LOWERING AGENTS ATORVASTATIN AND SIMVASTATIN WITH ROSUVASTATIN IN HIGH RISK SUBJECTS WITH TYPE IIA AND IIB HYPERCHOLESTEROLEMIA

(PRINCIPAL INVESTIGATOR, 2002)

A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED TRIAL TO DETERMINE THE LIPID-LOWERING EFFICACY AND SAFETY OF BMS 298585 ALONE AND IN COMBINATION WITH PRAVASTATIN IN SUBJECTS WITH MIXED DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2002)

A 48 WEEK OPEN LABEL, NON-COMPARATIVE, MULTICENTRE, PHASE IIIB, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE LIPID-REGULATING AGENT ROSUVASTATIN IN THE TREATMENT OF SUBJECTS WITH FREDRICKSON TYPE IIA AND TYPE IIB DYSLIPIDAEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2002)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 28 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE AND SIMVASTATIN CO-ADMINISTRATION VERSUS ATORVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2002)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CS 505 TABLETS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2002)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-5613 SUSTAINED -RELEASE FORMULATION PROTOTYPES IN SUBJECTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2002)

A 6-WEEK, OPEN-LABEL, DOSE-COMPARISON STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN, CERIVASTATIN, PRAVASTATIN, AND SIMVASTATIN IN SUBJECTS WITH HYPERCHOLESTEROLEMIA - EXTENSION
(PRINCIPAL INVESTIGATOR, 2002)

A 12 WEEK, RANDOMISED, DOUBLE-BLIND, FORCE-TITRATION, PARALLEL GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO COMPARE THE EFFICACY OF ROSUVASTATIN WITH ATORVASTATIN AND PLACEBO IN THE TREATMENT OF NON-DIABETIC, NON-ATHEROSCLEROSIS, METABOLIC SYNDROME SUBJECTS WITH RAISED LDL-C AND A 10 YEAR RISK FOR CHD OF > 10%
(PRINCIPAL INVESTIGATOR, 2002)

A COMPARISON OF TREATMENT WITH EZETIMIBE (SCH 58235) AND SIMVASTATIN COADMINISTRATION VERSUS SIMVASTATIN IN ATTAINING THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) ADULT TREATMENT PANEL (ATP) III CORONARY HEART DISEASE (CHD) OR CHD RISK EQUIVALENT STRATA LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGET LEVEL.
(PRINCIPAL INVESTIGATOR, 2002)

A 6-WEEK, OPEN-LABEL, DOSE-COMPARISON STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN, CERIVASTATIN, PRAVASTATIN, AND SIMVASTATIN IN SUBJECTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2001)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY, SAFETY, AND TOLERABILITY OF SCH 58235 (EZETIMIBE) WHEN ADDED TO THERAPY WITH AN HMG-COA REDUCTASE INHIBITOR (STATIN) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WITH KNOWN HEART DISEASE OR MULTIPLE RISK FACTORS - 1 YEAR EXTENSION
(PRINCIPAL INVESTIGATOR, 2001)

IMPACT STUDY (THE IMPACT OF MEDICAL SUBSPECIALTY ON PATIENT COMPLIANCE TO TREATMENT)
(PRINCIPAL INVESTIGATOR, 2001)

PHASE 2 MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP, DOSE RANGING STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF AN ORAL FORMULATION OF CP - 529,414 ADMINISTERED BID FOR 8 WEEKS TO SUBJECTS WITH MODERATE ELEVATIONS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND WITHOUT OVER CARDIOVASCULAR DISEASE.
(PRINCIPAL INVESTIGATOR, 2001)

PHASE 2 MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP, DOSE RANGING STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF A ORAL FORMULATION OF CP - 529,414 ADMINISTERED BID ON A BACKGROUND OF ATORVASTATIN 20 MG / DAY FOR 8 WEEKS TO SUBJECTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND WITHOUT OVERT CARDIOVASCULAR DISEASE.
(PRINCIPAL INVESTIGATOR, 2001)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL STUDY TO EVALUATE THE GLUCOSE AND LIPID-ALTERING EFFICACY AND SAFETY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES - EXTENSION
(PRINCIPAL INVESTIGATOR, 2001)

THE ANTHEM TRIAL (ADVICOR IN THE TREATMENT OF DIABETIC PATIENTS WITH DYSLIPIDEMIA USING THIAZOLIDINEDIONE AND/OR METFORMIN)
(PRINCIPAL INVESTIGATOR, 2001)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN MONOTHERAPY COMPARED WITH SIMVASTATIN PLUS EZETIMIBE IN TYPE 2 DIABETIC PATIENTS TREATED WITH THIAZOLIDINEDIONES
(PRINCIPAL INVESTIGATOR, 2001)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, BALANCED, THREE-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY OF SIMVASTATIN THERAPY IN ELEVATING HDL-C LEVELS IN PATIENTS WITH TYPE 2 DIABETIC DYSLIPIDEMIA AND LOW HDL-C - SIMVASTATIN IN LOW HDL IN DIABETES TRIAL OF EFFICACY (SILHOUETTE)
(PRINCIPAL INVESTIGATOR, 2001)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, "FACTORIAL" DESIGN, 48 WEEK EXTENSION STUDY TO EVALUATE THE SAFETY OF SCH 58235 10 MG/DAY COADMINISTERED WITH MULTIPLE DOSES OF SIMVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (EXTENSION)
(PRINCIPAL INVESTIGATOR 2001)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, "FACTORIAL" DESIGN, 12 WEEK STUDY TO EVALUATE THE EFFICACY OF SCH 58235 10 MG/DAY COADMINISTERED WITH MULTIPLE DOSES OF SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 2001)

A DOSE-RANGING STUDY OF NK-104 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 2001)

A DOSE-RANGING STUDY OF NK-104 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA - SLIT LAMP EXAMINATION SUB-STUDY
(PRINCIPAL INVESTIGATOR 2001)

DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING TRIAL TO EVALUATE THE EFFICACY OF ATORVASTATIN ON BONE MINERAL DENSITY AND MARKERS FOR BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH DYLIPIDEMIA AND AT RISK FOR OSTEOPOROSIS
(PRINCIPAL INVESTIGATOR 2001)

EFFECTS OF ORAL NO-1886 ON LIPOPROTEINS IN SUBJECTS WITH TYPE II DIABETES MELLITUS WHO ARE RECEIVING STATIN THERAPY
(PRINCIPAL INVESTIGATOR, 2001)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SD-5613 AS MONOTHERAPY IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (MONOTHERAPY ASSESSMENT OF REDUCING CHOLESTEROL) [MONARCH].
(PRINCIPAL INVESTIGATOR 2001)

A 16-WEEK, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFECT OF AVASIMIBE IN COMBINATION WITH ATORVASTATIN ON LIPIDS IN PATIENTS WITH TYPE IIA AND IIB DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2000)

LONG-TERM, OPEN-LABEL, SAFETY STUDY WITH SD-5613
(PRINCIPAL INVESTIGATOR, 2000)

AN EIGHT WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER STUDY IN HYPERCHOLESTEROLEMIC PATIENTS TO DETERMINE THE EFFICACY AND SAFETY OF COMBINATION THERAPY WITH CI-1027 AND A STATIN
(PRINCIPAL INVESTIGATOR, 2000)

PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY (PROVE IT)
(PRINCIPAL INVESTIGATOR, 2000)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH SIMVASTATIN IN THIAZOLIDINEDIONE-TREATED (PIOGLITAZONE OR ROSIGLITAZONE) TYPE 2 DIABETIC PATIENTS
(PRINCIPAL INVESTIGATOR, 2000)

FENOFIBRATE AND CERIVASTATIN TRIAL OPTIMIZING RESPONSE (FACTOR). A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, STUDY OF THE SAFETY AND EFFICACY OF CERIVASTATIN IN COMBINATION WITH FENOFIBRATE COMPARED TO CERIVASTATIN ALONE, FENOFIBRATE ALONE, AND PLACEBO IN A POPULATION OF TYPE 2 DIABETIC MEN AND WOMEN
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY, SAFETY, AND TOLERABILITY OF SCH 58235 (EZETIMIBE) WHEN ADDED TO THERAPY WITH AN HMG-COA REDUCTASE INHIBITOR (STATIN) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WITH KNOWN HEART DISEASE OR MULTIPLE RISK FACTORS
(PRINCIPAL INVESTIGATOR, 2000)

A PHASE III DOUBLE-BLIND EFFICACY AND SAFETY STUDY OF SCH 58235 (10MG) IN ADDITION TO ATORVASTATIN COMPARED TO PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2000)

PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF ORAL CP - 529,414 SOFT-GEL CAPSULES IN SUBJECTS WITH LOW HIGH DENSITY LIPOPROTEIN CHOLESTEROL
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL, 28 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN 80 MG/DAY VERSUS ATORVASTATIN 80 MG/DAY IN PATIENTS WITH HYPERCHOLESTEROLEMIA (CHESS: COMPARATIVE HDL EFFICACY AND SAFETY STUDY)
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF GL262570 SODIUM TABLETS (2.5 MG, 5 MG, AND 7.5 MG) ADMINISTERED AS A DAILY DOSE FOR 8 WEEKS IN SUBJECTS WITH DYSLIPIDEMIA.

(PRINCIPAL INVESTIGATOR, 2000)

AN OPEN-LABEL, RANDOMIZED STUDY OF THE RELATIVE EFFICACY OF NICOSTATIN COMPARED TO SIMVASTATIN AND ATORVASTATIN
(PRINCIPAL INVESTIGATOR, 2000)

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, DOSE-RANGING STUDY OF SD-5613 AS MONOTHERAPY AND IN COMBINATION THERAPY WITH ATORVASTATIN (ASSESSMENT OF CHOLESTEROL REDUCTION BY AN INHIBITOR OF THE ILEAL BILE ACID TRANSPORTER SD-5613 (ACRIIBAT)
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, PARALLEL, 48-WEEK EXTENSION, 3-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF L-654969 IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2000)

WELCHOL LECTURE BUREAU CHART REVIEW PROGRAM
(PRINCIPAL INVESTIGATOR 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO- AND ACTIVE-COMPARATOR-CONTROLLED, PARALLEL STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY, SAFETY, AND TOLERABILITY OF L-410198 IN PATIENTS WITH MIXED HYPERLIPIDEMIA (ELEVATED CHOLESTEROL AND TRIGLYCERIDES)

(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO- AND ACTIVE-COMPARATOR-CONTROLLED, PARALLEL STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY, SAFETY, AND TOLERABILITY OF L-410198 IN PATIENTS WITH MIXED HYPERLIPIDEMIA (ELEVATED CHOLESTEROL AND TRIGLYCERIDES) - ECHOCARDIOGRAPHIC SUBSTUDY
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL, 12-WEEK, 4-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF L-654969 IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED, PARALLEL, STUDY TO EVALUATE THE GLUCOSE-LOWERING EFFICACY, LIPID-ALTERING EFFICACY, SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED, PARALLEL, STUDY TO EVALUATE THE GLUCOSE-LOWERING EFFICACY, LIPID-ALTERING EFFICACY, SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES - ECHOCARDIOGRAPHIC SUBSTUDY
(PRINCIPAL INVESTIGATOR, 2000)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF ONCE PER DAY VS. SPLIT DOSING OF SEVELAMER HYDROCHLORIDE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 2000)

AN OPEN-LABEL, MULTINATIONAL, MULTICENTRE, EXTENSION TRIAL TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ZD4522 IN SUBJECTS IN THE ZD4522 CLINICAL TRIAL PROGRAM
(PRINCIPAL INVESTIGATOR, 1999)

A 12 WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CI-1027 IN PATIENTS WITH LOW HDL-C AND EITHER NORMAL OR ELEVATED TRIGLYCERIDES
(PRINCIPAL INVESTIGATOR, 1999)

LONG TERM, OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF SCH 58235 IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (EXTENSION)
(PRINCIPAL INVESTIGATOR, 1999)

DOSE-RESPONSE EFFECTS OF ORAL NO-1886 ON LIPOPROTEINS IN SUBJECTS WITH DECREASED HDL-C LEVELS
(PRINCIPAL INVESTIGATOR, 1999)

PHASE II, DOSE-RESPONSE STUDY OF ORAL NO-1886 IN SUBJECTS WITH MARKED HYPERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A COMPARATIVE STUDY OF LOVASTATIN XL WITH MEVACOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, PILOT STUDY TO ASSESS THE 4-WEEK SAFETY AND EFFICACY OF ORAL 264W94 ADMINISTERED AS MONOTHERAPY (8 MG BID, 32 MG BID) AND COMBINATION THERAPY (8MG BID PLUS 20 MG ZOCOR QD) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A SIX WEEK, RANDOMIZED DOUBLE-BLIND MULTICENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ZD4522 (5, 10, 20, 40, AND 80 MG) AND ATORVASTATIN (10, 20, 40, AND 80 MG) ACROSS THEIR RESPECTIVE DOSE RANGES IN THE TREATMENT OF SUBJECTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A TWELVE WEEK MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZD4522 (5,10,20,40 AND 80 MG) IN THE TREATMENT OF SUBJECTS WITH HYPERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A PHASE III, DOUBLE BLIND, EFFICACY AND SAFETY STUDY OF ONE DOSE OF SCH 58235 10MG COMPARED TO PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

AN EXTENDED SAFETY, EFFICACY AND TOLERABILITY STUDY OF LOVASTATIN XL IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

CERIVASTATIN FOR HYPERLIPIDEMIA AFTER REACHING MENOPAUSE (CHARM): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP, 6 -WEEK EVALUATION OF CERIVASTATIN 0.4 MG AND ATORVASTATIN 10 MG IN POST MENOPAUSAL WOMEN WITH HYPERLIPIDEMIA AND A 46 WEEK EVALUATION IN WHICH CERIVASTATIN 0.4 MG AND CERIVASTATIN 0.8 MG ARE COMPARED TO FENOFIBRATE 201 MG FOR LONG-TERM LIPID-LOWERING AND BONE MINERAL DENSITY EFFECTS.
(PRINCIPAL COINVESTIGATOR, 1999)

A RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL TO COMPARE THE SHORT-TERM AND LONG-TERM EFFICACY AND SAFETY OF ZD4522, SIMVASTATIN, AND PRAVASTATIN IN THE TREATMENT OF SUBJECTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A PHASE II DOUBLE BLIND DOSE RESPONSE INVESTIGATION OF THE EFFICACY AND SAFETY OF FOUR DOSES OF SCH 58235 COMPARED TO PLACEBO IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A STUDY TO EVALUATE THE DEGREE OF CORRELATION BETWEEN HEPATIC ULTRASOUND, COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING AS METHODS TO DETECT POTENTIAL FAT INFILTRATION OF THE LIVER FOLLOWING 80 AND 160 MG BAY 13-9952, OR PLACEBO DOSED ONCE DAILY FOR 28 DAYS IN HYPERCHOLESTEROLEMIC PATIENTS.
(PRINCIPAL INVESTIGATOR, 1999)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP EVALUATION OF CERIVASTATIN 0.8 MG COMPARED TO CERIVASTATIN 0.4 AND PLACEBO ONCE DAILY IN PATIENTS WITH HYPERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF GT 102-279 ALONE AND IN COMBINATION WITH LOVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 2 PERIOD, COMPLETE BLOCK, CROSSOVER STUDY TO EVALUATE THE EFFICACY OF L-654969 AND SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1999)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL, 36 WEEK DOSE ESCALATION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN 40 AND 80 MG/DAY VERSUS ATORVASTATIN 20, 40, AND 80 MG/DAY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1998)

A LONG-TERM, OPEN-LABEL, MULTI-CENTER TRIAL OF THE SAFETY AND EFFICACY OF NICOSTATIN IN PATIENTS WITH DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 1998)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF COLESEVELAM HYDROCHLORIDE AND SIMVASTATIN ALONE AND IN COMBINATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1998)

EFFICACY COMPARISON OF DIFFERENT FORMULATIONS OF PRAVASTATIN 40MG
(PRINCIPAL INVESTIGATOR, 1998)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SIMVASTATIN IN THERAPY IN PATIENTS WITH HYPERTRIGLYCERIDEMIA
(PRINCIPAL INVESTIGATOR, 1998)

A 54 WEEK OPEN LABEL ASSESSMENT OF THE SAFETY AND EFFICACY PROFILE OF ATORVASTATIN AS COMPARED TO FLUVASTATIN, LOVASTATIN, SIMVASTATIN, AND PRAVASTATIN WHEN USED TO OPTIMALLY CONTROL PRIMARY HYPERCHOLESTEROLEMIA (IIA) AND MIXED DYSLIPIDEMIA (TYPE IIB)
(PRINCIPAL INVESTIGATOR, 1997)

PILOT DOSE-RANGING STUDY OF THE SAFETY AND EFFICACY OF SCH 58235 COMPARED TO PLACEBO AND LOVASTATIN IN PATENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1997)

SCREENING PROCEDURE FOR IDENTIFICATION OF SUBJECTS FOR PARTICIPATION IN A PILOT DOSE-RANGING STUDY OF THE SAFETY AND EFFICACY OF SCH 58235 COMPARED TO PLACEBO AND LOVASTATIN IN PATENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1997)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP EVALUATION OF CERIVASTATIN 0.8 MG COMPARED TO CERIVASTATIN 0.4 MG
AND PLACEBO/PRAVASTATIN 40 MG ONCE DAILY IN PATENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1997)

A RANDOMIZED, DOUBLE-BLIND TRIAL OF CHOLESTAGEL (2.4G, 3.2G, 4.0G, 4.8G) VS PLACEBO IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1997)

MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-PERIOD BALANCED CROSSOVER STUDY TO EVALUATE THE EFFICACY OF SIMVASTATIN THERAPY IN PATIENTS WITH COMBINED HYPERLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 1997)

A DOUBLE-BLIND, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF NIASPAN (CONTROLLED-RELEASE NIACIN) VERSUS GEMFIBROZIL PATIENTS WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL
(PRINCIPAL INVESTIGATOR, 1997)

A FOUR YEAR, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION OF CHD IN PATIENTS WITH TYPE II NONINSULIN-DEPENDENT DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 1996)

A FOUR YEAR, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION AS PREVENTION OF CHD END POINTS (RETINOPATHY) IN PATIENTS WITH TYPE II NONINSULIN-DEPENDENT DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 1996)

MULTICENTER, DOUBLE-BLIND, 4-ARM, PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN GEM 80 AND 160 MG IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1996)

MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO DETERMINE THE LDL-C LOWERING EFFICACY OF PRAVASTATIN ADMINISTERED ONCE DAILY OVER THE DOSAGE RANGE OF 40MG THOROUGH 160 MG
(PRINCIPAL INVESTIGATOR, 1996)

RESEARCH COMPLETED TRIALS MULTICENTER, DOUBLE BLIND, TWO-ARM, PARALLEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HIGH DOSE SIMVASTATIN IN HYPERCHOLESTEROLEMIC PATIENTS - EXTENSION STUDY
(PRINCIPAL INVESTIGATOR, 1996)

MULTICENTER, DOUBLE-BLIND, 2-ARM, PARALLEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HIGH-DOSE SIMVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1996)

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECTS OF SIMVASTATIN 80 MG A DAY ON STEROID HORMONE PRODUCTION IN MEN
(PRINCIPAL INVESTIGATOR, 1996)

PILOT EVALUATION OF THE PHARMACOKINETICS OF NICOTINIC ACID AND ITS MAJOR METABOLITES FOLLOWING MULTIPLE DOSE ADMINISTRATION OF NIACOR-SR
(PRINCIPAL INVESTIGATOR, 1996)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP EVALUATION OF CERIVASTATIN COMPARED TO FLUVASTATIN 40MG AND PLACEBO DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR, 1996)

EXTENDED ACCESS TREATMENT PROTOCOL FOR THE USE OF ATORVASTATIN IN PATIENTS WHO PARTICIPATED IN PRIOR PROTOCOLS
(PRINCIPAL INVESTIGATOR, 1996)

ATORVASTATIN/DIABETES EXTENSION STUDY
(PRINCIPAL INVESTIGATOR, 1995)

MULTICENTER, OPEN-LABEL, TRIAL OF THE LONG-TERM SAFETY AND EFFICACY OF NIASPAN IN PATIENTS WITH PRIMARY HYPERLIPOPROTEINEMIA
(PRINCIPAL INVESTIGATOR 1994)

THE NIACIN STUDY - NIACOR-SR VS. IMMEDIATE RELEASE NIACIN
(PRINCIPAL INVESTIGATOR 1994)

LONGTERM SAFETY AND EFFICACY OF NIACOR-SR TABLETS IN THE TREATMENT OF HYPERLIPIDEMIA
(PRINCIPAL INVESTIGATOR 1994)

A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP 6-MONTH STUDY OF THE EFFECT OF CERIVASTATIN COMPARED TO LOVASTATIN 40 MG ONCE DAILY ON SEMEN PRODUCTION AND ADRENAL AND REPRODUCTIVE HORMONE FUNCTION IN MALE PATIENTS WITH HYPERCHOLESTEROLEMIA.
(PRINCIPAL INVESTIGATOR 1994)

A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, 6-WEEK, DOSE-RANGING STUDY OF ONCE DAILY ATORVASTATIN IN PATIENTS WITH ELEVATED LDL-CHOLESTEROL.
(PRINCIPAL INVESTIGATOR, 1994)

MULTI-CENTER QUALIFICATION TRIAL FOR ENTRY INTO THE MULTI-CENTER, OPEN-LABEL TRIAL OF THE LONG-TERM SAFETY AND EFFICACY OF NIASPAN IN PATIENTS WITH PRIMARY HYPERLIPOPROTEINEMIA
(PRINCIPAL INVESTIGATOR 1994)

NIACIN DIET TRIAL
(PRINCIPAL INVESTIGATOR 1994)

DOUBLE BLIND STUDY OF A ATORVASTATIN COMPARED TO SIMVASTATIN IN LOWERING CHOLESTEROL IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS PATIENTS WITH DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR 1994)

FIRST EXTENSION DOUBLE BLIND DOSE-RANGING STUDY OF CERIVASTATIN IN DOSES OF 25UG, 50UG, 100UG, AND 200UG ONCE DAILY COMPARED TO PLACEBO AND TO LOVASTATIN 40MG ONCE DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 1993)

SECOND EXTENSION DOUBLE BLIND DOSE-RANGING STUDY OF CERIVASTATIN IN DOSES OF 25UG, 50UG, 100UG, AND 200UG ONCE DAILY COMPARED TO PLACEBO AND TO LOVASTATIN 40MG ONCE DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 1993)

THIRD EXTENSION DOUBLE BLIND DOSE-RANGING STUDY OF CERIVASTATIN IN DOSES OF 25UG, 50UG, 100UG, AND 200UG ONCE DAILY COMPARED TO PLACEBO AND TO LOVASTATIN 40MG ONCE DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 1993)

A PHASE II PIVOTAL STUDY TO EVALUATE EFFICACY AND SAFETY OF SCH 48461 IN SUBJECTS WITH HYPERCHOLESTEROLEMIA.
(PRINCIPAL INVESTIGATOR 1993)

OPEN-LABEL STUDY OF FLUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA IN CLINICAL PRACTICE SETTINGS
(PRINCIPAL INVESTIGATOR 1993)

DOUBLE BLIND DOSE-RANGING STUDY OF CERIVASTATIN IN DOSES OF 25UG, 50UG, 100UG, AND 200UG ONCE DAILY COMPARED TO PLACEBO AND TO LOVASTATIN 40MG ONCE DAILY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
(PRINCIPAL INVESTIGATOR 1992)

PRAVASTATIN ENDOCRINE STUDY IN MEN
PRINCIPAL INVESTIGATOR (1992)

PRAVASTATIN ENDOCRINE STUDY IN WOMEN
(PRINCIPAL INVESTIGATOR 1992)

CHOLESTEROL SEQUESTRANT PHASE II STUDY
(CO-INVESTIGATOR 1992)

LIFIBROL (A NOVEL CHOLESTEROL LOWERING AGENT) DOSE-RANGING STUDY IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (1992)

PRAVASTATIN SPECIAL PATIENT POPULATION STUDY
PRINCIPAL INVESTIGATOR (1992)

R.E.M. (RESIN ENROBED METHOCEL) I STUDY
(PRINCIPAL INVESTIGATOR 1991)

R.E.M. (RESIN ENROBED METHOCEL) II STUDY
(PRINCIPAL INVESTIGATOR 1991)

L.A.S. (LOVASTATIN ADOLESCENT STUDY) STUDY
CO-INVESTIGATOR (1991)

S.E.L.E.C.T. (SELECOR'S EFFECT LOWERING BP IN THOSE WITH ELEVATED CHOLESTEROL/TRIGLYCERIDES) STUDY
(PRINCIPAL INVESTIGATOR 1991)

 

L-MARC HOME PAGE